Smith Group Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-1,010
| Closed | -$72K | – | 415 |
|
|
2019
Q2 | $72K | Hold |
1,010
| – | – | ﹤0.01% | 255 |
|
|
2019
Q1 | $79K | Sell |
1,010
-3,046
| -75% | -$238K | ﹤0.01% | 272 |
|
|
2018
Q4 | $343K | Sell |
4,056
-160
| -4% | -$13.5K | 0.01% | 210 |
|
|
2018
Q3 | $722K | Buy |
4,216
+818
| +24% | +$140K | 0.02% | 187 |
|
|
2018
Q2 | $439K | Hold |
3,398
| – | – | 0.01% | 202 |
|
|
2018
Q1 | $350K | Sell |
3,398
-2,886
| -46% | -$297K | 0.01% | 211 |
|
|
2017
Q4 | $537K | Hold |
6,284
| – | – | 0.02% | 205 |
|
|
2017
Q3 | $534K | Hold |
6,284
| – | – | 0.02% | 211 |
|
|
2017
Q2 | $476K | Hold |
6,284
| – | – | 0.01% | 218 |
|
|
2017
Q1 | $415K | Sell |
6,284
-16
| -0.3% | -$1.06K | 0.01% | 199 |
|
|
2016
Q4 | $399K | Hold |
6,300
| – | – | 0.01% | 201 |
|
|
2016
Q3 | $401K | Buy |
6,300
+818
| +15% | +$52.1K | 0.01% | 195 |
|
|
2016
Q2 | $408K | Sell |
5,482
-177
| -3% | -$13.2K | 0.01% | 194 |
|
|
2016
Q1 | $378K | Buy |
+5,659
| New | +$378K | 0.01% | 175 |
|
|
2014
Q4 | – | Sell |
-32,251
| Closed | -$945K | – | 432 |
|
|
2014
Q3 | $945K | Sell |
32,251
-112
| -0.3% | -$3.28K | 0.04% | 178 |
|
|
2014
Q2 | $1.26M | Sell |
32,363
-1,252
| -4% | -$48.7K | 0.05% | 173 |
|
|
2014
Q1 | $1.41M | Sell |
33,615
-264
| -0.8% | -$11.1K | 0.05% | 169 |
|
|
2013
Q4 | $1.11M | Buy |
+33,879
| New | +$1.11M | 0.04% | 176 |
|